Opposition to the Affordable Care Act has dropped by seven percentage points since early January, before Donald Trump became president. » Read More
A Republican push to repeal and replace Obamacare has slowed amid concerns over large numbers of people losing health coverage. » Read More
Shkreli is accused of ripping off his former pharma company Retrophin to pay off hedge-fund investors he was accused of defrauding. » Read More
By: Rachel Cao
Shares of Bristol-Myers climbed as much as 4 percent after billionaire Carl Icahn reportedly took a stake in the company, according to Dow Jones. » Read More
Health-care stocks haven't gotten the green light many expected from Hillary Clinton's election loss.
Ryan and his House GOP colleagues have tried numerous times to repeal the law but were never able to during Obama's tenure.
Researchers have found a functional link between gut bacteria and Parkinson's disease.
Kenneth Frazier, the CEO of pharmaceutical giant Merck, says Trump's call to revamp Obamacare could prove useful.
Scientists are taking a new approach to the riddle of preterm birth, which kills 1 million babies globally each year.
One woman explains how the President-elect's actions on Obamacare could actually threaten her life.
In the likely repeal of the Affordable Care Act, these health-care stocks should perform well, according to some analysts.
Everyone from government to independent foundations are funding microbiome research. Why bacteria's DNA is garnering so much attention.
President-elect Donald Trump will choose Georgia Rep. Tom Price to head the Department of Health and Human Services, a source told NBC News.
Overturning Obamacare without plunging the health system into chaos may be easier said than done.
Health spending on privately insured people rose 4.6 percent, with much of the increase coming from prescription drugs and medical services.
Hospitals that benefited under Obamacare likely will see a reversal of fortune and there are new risks for already struggling insurers.
Juno Therapeutics shares shed 24 percent Wednesday after the biopharmaceutical company announced complications with its Phase II clinical trial of JCAR015.
Solanezumab, an experimental drug from Eli Lilly, failed to slow the loss of cognitive ability in patients with mild Alzheimer's disease.
You might survive going to the emergency room — but the "surprise" bill you get later could be a real killer.
One-third of U.S. adults reported not getting recommended health care and not going to the doctor when sick because of the costs.
The tally represents a slight uptick in health plan selections compared with the same time period last year.
Zika can survive in a highly contagious form outside a host, such as on a table or counter. But common chemicals can kill it.
Chinese scientists are first to inject a person with gene-edited cells using the CRISPR technique. This could be America's biotech Sputnik.
One anti-anxiety drug, Ativan, had an average unit cost increase of a stunning 1,264 percent between 2014 and 2015 for Medicaid.
Get the best of CNBC in your inbox